Currently, antibody drugs play an important and integral role in both biopharmaceuticals and basic research. Achieving the rational design, manufacture and use of antibodies for the diagnosis and treatment of various diseases has long been a goal pursued by pharmaceutical researchers. Antibodies have the characteristics of specific recognition of antigens and high affinity for target antigens. This is the basis for researchers' ability to use antibodies in a wide range of applications, including target antigen screening, diagnostic biomarker discovery, and antibody-based drug design and manufacturing. The figure below illustrates the major discovery journeys of antibody drugs.
Figure.1 The general flow of antibody discovery.
Antibody discovery begins with the target antigen. Antibody discovery begins with the target antigen, followed by a series of antibody screening and druggability validation processes. After identifying the drug target, how to obtain the target candidate antibody molecules quickly and efficiently is one of the most important concerns for researchers of antibody drugs. At CD Genomics, we have achieved a significant reduction in antibody screening frequency while increasing the accuracy of the screening process by introducing the NGS-based high-throughput technology platform. If you have any antibody development needs, please consider our antibody discovery solutions.
CD Genomics is committed to advancing your antibody drug development process, improving the efficiency of antibody screening while maintaining quality. By incorporating the high-throughput NGS technology platform into the antibody discovery process, we can provide a new experience for your antibody discovery program. Our optimized antibody discovery solutions will have important applications for research in antibody drug manufacturing, and disease diagnosis, focusing on the following two areas.
CD Genomics has introduced NGS into the phage display workflow, which not only greatly improves the efficiency of specific antibody screening, but also provides deeper and more comprehensive coverage. Our antibody display sequencing is mainly used to detect the antibody gene composition and respective abundance of antibody libraries to perform pre-experimental quality control work. In addition, antibody library sequencing can be used to discover antibody sequences that bind with high affinity to antigens and can be used for downstream optimization of synthetic expression.
CD Genomics can provide you with NGS-based immunoassay services focused on ultra-deep sequencing around the V(D)J region to fully characterize the entire BCR/TCR library and antibody library This is an important basis in the antibody discovery process. Analysis targeting variable regions will provide greater insight into immune cell differentiation, BCR somatic hypermutation, class switching and antigen specificity for application in biomarker discovery, tracking of known library sequences and disease research.
CD Genomics is committed to combining professional project protocol guidance and standardized analysis processes to ensure that your project is performed accurately and quickly. If you are interested in CD Genomics' antibody discovery solutions, please feel free to contact us now.
CD Genomics is transforming biomedical potential into precision insights through seamless sequencing and advanced bioinformatics.
